Biotechnology M&A » By The Online Investor Staff, updated Tue., Apr. 23, 7:35 AM
Recent mergers and acquisitions in the Biotechnology M&A category.
| This Slide: #17 of 83 |
Slide #17. Alnylam Pharmaceuticals, Inc. — Merck's Sirna Therapeutics Subsidiary
Acquirer:
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Acquiree:
Merck's Sirna Therapeutics Subsidiary
Details:
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading RNAi therapeutics company, announced today that the previously announced acquisition of Merck's wholly owned subsidiary Sirna Therapeutics, Inc. ("Sirna Therapeutics" or "Sirna") has closed, following the expiration of the Hart-Scott-Rodino waiting period. On January 10, 2014, Alnylam entered into a stock purchase agreement with Merck pursuant to which Alnylam agreed to purchase from Merck all of Merck's rights, title, and interest in and to all of the outstanding shares of common stock of Sirna Therapeutics. In consideration for the Sirna common stock, Alnylam paid Merck $25.0 million in cash. In addition, Alnylam agreed to issue to Merck 2,520,044 shares of Alnylam common stock, having a value of $150.0 million as calculated under the terms of the stock purchase agreement on the date of execution, and representing an approximately 3% ownership position in Alnylam's outstanding common stock. Alnylam issued 85% of the shares at the closing and will issue the remainder of shares upon the completion of certain technology transfer activities pursuant to the terms of the stock purchase agreement.
Alnylam Pharmaceuticals is a global biopharmaceutical company developing therapeutics based on ribonucleic acid interference (RNAi). Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of primary hyperoxaluria type 1 in all age groups. Leqvio (inclisiran) is being developed and commercialized for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.
ALNY SEC Filing Email Alerts Service
Open the ALNY Page at The Online Investor »
|
|||||||||||||||||||||
Open the ALNY Page at The Online Investor (in a new window) »
 Free ALNY Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Buy (3.16 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: ALNY Stock Forecast Based on Zacks ABR data; powered by Xignite |
